Colinz Laboratories Ratios

Colinz Laboratories Ltd Ratios

The Colinz Laboratories Ltd Ratios page provides a complete fundamental analysis of Colinz Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Colinz Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Colinz Laboratories Ltd (NSE: , BSE: 531210) is currently trading at ₹43.47, with a market capitalization of ₹104.54M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Colinz Laboratories Ltd remains a key stock for fundamental analysis using Colinz Laboratories Ltd Ratios.

Colinz Laboratories Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Colinz Laboratories Ltd P/E ratio currently stands at 36.75, making it one of the most tracked metrics in Colinz Laboratories Ltd Ratios.

Historically, the Colinz Laboratories Ltd P/E ratio has shown strong fluctuations:

• 2024: 36.75
• 2023: 19.44
• 2022: 19.28
• 2021: 31.73
• 2020: 16.74

The rising Colinz Laboratories Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Colinz Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.93.

Historical P/B trend:

• 2024: 1.93
• 2023: 1.06
• 2022: 1.08
• 2021: 1.40

Colinz Laboratories Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Colinz Laboratories Ltd P/S ratio currently stands at 2.80, an important part of Colinz Laboratories Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.80
• 2023: 1.35
• 2022: 1.23
• 2021: 1.54

The rising Colinz Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.

Colinz Laboratories Ltd Price to Cash Flow Ratio (P/CF)

The Colinz Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Colinz Laboratories Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 9.70
• 2022: 12.02
• 2021: 10.06
• 2020: 2.13

The declining Colinz Laboratories Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Colinz Laboratories Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Colinz Laboratories Ltd EV currently stands at ₹133.39M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 133.39M
• 2023: 30.29M
• 2022: 33.61M
• 2021: 60.43M

Colinz Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Colinz Laboratories Ltd EV/EBITDA ratio is currently 26.83, a key metric in Colinz Laboratories Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 26.83
• 2023: 5.58
• 2022: 5.31
• 2021: 10.31

Higher Colinz Laboratories Ltd EV/EBITDA suggests premium valuation.

Colinz Laboratories Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Colinz Laboratories Ltd D/E ratio is currently 0.07, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.07
• 2023: 0.06
• 2022: 0.03
• 2021: 0.06

Colinz Laboratories Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Colinz Laboratories Ltd ROE currently stands at 5.39%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 5.39
• 2023: 5.70
• 2022: 5.78
• 2021: 4.53

Declining ROE indicates pressure on profitability.

Colinz Laboratories Ltd Ratios Analysis Summary

The Colinz Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Colinz Laboratories Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Colinz Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.